within Pharmacolibrary.Drugs.ATC.L;

model L01AA09
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.01065,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.020300000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0054,
    k12             = 722,
    k21             = 722
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01AA09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Bendamustine is an alkylating antineoplastic agent used primarily in the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (NHL), and multiple myeloma. It is administered intravenously, and is approved for medical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma after intravenous infusion.</p><h4>References</h4><ol><li><p>Cracchiolo, MJ, et al., &amp; Katsanis, E (2024). Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies. <i>Cancer chemotherapy and pharmacology</i> 94(3) 361–372. DOI:<a href=&quot;https://doi.org/10.1007/s00280-024-04688-y&quot;>10.1007/s00280-024-04688-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38878208/&quot;>https://pubmed.ncbi.nlm.nih.gov/38878208</a></p></li><li><p>Darwish, M, et al., &amp; Chovan, JP (2015). Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. <i>Cancer chemotherapy and pharmacology</i> 75(6) 1143–1154. DOI:<a href=&quot;https://doi.org/10.1007/s00280-015-2727-6&quot;>10.1007/s00280-015-2727-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25829094/&quot;>https://pubmed.ncbi.nlm.nih.gov/25829094</a></p></li><li><p>Jairam, RK, et al., &amp; Mullangi, R (2019). Prediction of Human Pharmacokinetics of Bendamustine from Preclinical Species Pharmacokinetics Based on Normalizing Time Course Profiles. <i>Drug research</i> 69(1) 32–39. DOI:<a href=&quot;https://doi.org/10.1055/a-0640-8977&quot;>10.1055/a-0640-8977</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29996173/&quot;>https://pubmed.ncbi.nlm.nih.gov/29996173</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01AA09;
